Viviane Nunes

Dr. Viviane Nunes

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAndressa Cristina Antunes Santos
Andressa Cristina Antunes Santos
Denisse Mallaupoma CamarenaDenisse Mallaupoma Camarena
Denisse Mallaupoma Camarena
GRGustavo Roncoli Reigado
Gustavo Roncoli Reigado
FCFelipe Santiago Chambergo
Felipe Santiago Chambergo
VNViviane Nunes
Viviane Nunes
SMSilvya Maria-Engler
Silvya Maria-Engler
Cultivated meat (CM) technology has the potential to disrupt the food industry—indeed, it is already an inevitable reality. This new technology is an alternative to solve the environmental, health and ethical issues associated with the demand for meat products. The global market longs for biotechnological improvements for the CM production chain. CM, also known as cultured, cell-based, lab-grown, in vitro or clean meat, is obtained through cellular agriculture, which is based on applying tissue engineering principles. In practice, it is first necessary to choose the best cell source and type, and then to furnish the necessary nutrients, growth factors and signalling molecules via cultivation media. This procedure occurs in a controlled environment that provides the surfaces necessary for anchor-dependent cells and offers microcarriers and scaffolds that favour the three-dimensional (3D) organisation of multiple cell types. In this review, we discuss relevant information to CM production, including the cultivation process, cell sources, medium requirements, the main obstacles to CM production (consumer acceptance, scalability, safety and reproducibility), the technological aspects of 3D models (biomaterials, microcarriers and scaffolds) and assembly methods (cell layering, spinning and 3D bioprinting). We also provide an outlook on the global CM market. Our review brings a broad overview of the CM field, providing an update for everyone interested in the topic, which is especially important because CM is a multidisciplinary technology.

12 February 2025 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
NANathalia Silva Dutra Alves
Nathalia Silva Dutra Alves
GRGustavo Roncoli Reigado
Gustavo Roncoli Reigado
MSMayara Santos
Mayara Santos
ICIzabela Daniel Sardinha Caldeira
Izabela Daniel Sardinha Caldeira
HHHenrique dos Santos Hernandes
Henrique dos Santos Hernandes
VNViviane Nunes
Viviane Nunes
Significant progress has been made in regenerative medicine for skin repair and rejuvenation. This review examines core technologies including stem cell therapy, bioengineered skin substitutes, platelet-rich plasma (PRP), exosome-based therapies, and gene editing techniques like CRISPR. These methods hold promise for treating a range of conditions, from chronic wounds and burns to age-related skin changes and genetic disorders. Challenges remain in optimizing these therapies for broader accessibility and ensuring long-term safety and efficacy.

19 March 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
JSJeniffer Farias dos Santos
Jeniffer Farias dos Santos
NBNathália Ruder Borçari
Nathália Ruder Borçari
MAMariana da Silva Araújo
Mariana da Silva Araújo
VNViviane Nunes
Viviane Nunes

1 April 2007 in Biology of the Cell
Verified
Journal Article
Closed access
PDF file
VNViviane Nunes
Viviane Nunes
NCNatale Cavaçana
Natale Cavaçana
MCMartha Canovas
Martha Canovas
BSBryan Strauss
Bryan Strauss
MZMAYANA ZATZ
MAYANA ZATZ

1 July 2005 in Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology
Verified
Journal Article
Closed access
VNViviane Nunes
Viviane Nunes
AGAndrezza J. Gozzo
Andrezza J. Gozzo
ICIlana Cruz-Silva
Ilana Cruz-Silva
MJMaria A. Juliano
Maria A. Juliano
TVTania A. Viel
Tania A. Viel
MAMariana S. Araujo
Mariana S. Araujo

1 January 2006 in Biological Chemistry
Verified
Journal Article
Closed access
AGAndrezza J. Gozzo
Andrezza J. Gozzo
VNViviane Nunes
Viviane Nunes
ICIlana Cruz-Silva
Ilana Cruz-Silva
ACAdriana Carmona
Adriana Carmona
HNHelena B. Nader
Helena B. Nader
MAMariana S. Araújo
Mariana S. Araújo
The interplay of different proteases and glycosaminoglycans is able to modulate the activity of the enzymes and to affect their structures. Human plasma kallikrein (huPK) is a proteolytic enzyme involved in intrinsic blood clotting, the kallikrein-kinin system and fibrinolysis. We investigated the effect of heparin on the action, inhibition and secondary structure of huPK. The catalytic efficiency for the hydrolysis of substrates by huPK was determined by Michaelis-Menten kinetic plots: 5.12x10(4) M-1 s-1 for acetyl-Phe-Arg-p-nitroanilide, 1.40x10(5) M-1 s-1 for H-D-Pro-Phe-Arg-p-nitroanilide, 2.25x10(4) M-1 s-1 for Abz-Gly-Phe-Ser-Pro-Phe-Arg-Ser-Ser-Arg-Gln-EDDnp, 4.24x10(2)M-1 s-1 for factor XII and 5.58x10(2) M-1 s-1 for plasminogen. Heparin reduced the hydrolysis of synthetic substrates (by 2.0-fold), but enhanced factor XII and plasminogen hydrolysis (7.7- and 1.4-fold, respectively). The second-order rate constants for inhibition of huPK by antithrombin and C1-inhibitor were 2.40x10(2) M-1 s-1 and 1.70x10(4) M-1 s-1, respectively. Heparin improved the inhibition of huPK by these inhibitors (3.4- and 1.4-fold). Despite the fact that huPK was able to bind to a heparin-Sepharose matrix, its secondary structure was not modified by heparin, as monitored by circular dichroism. These actions may have a function in the control or maintenance of some pathophysiological processes in which huPK participates.